Clinical Observation of Integrated Chinese Medicine With Western Medicine for the Reduction of Chemotherapy-induced Hematologic Toxicity

Completed

• Conditions: Myelosuppression

• Registration Number: NCT05442177
• Lead Sponsor: Taichung Tzu Chi Hospital

Brief Summary

We conducted an observational study to investigate the effectiveness and safety of Integrated Chinese Medicine With Western Medicine for bone marrow suppression induced by chemotherapy in patients with cancer. The TCM constitution and pulse diagnosis was also observed in the study.

Detailed Description

Patients with cancer under chemotherapy and integrated Western and Chinese medicine were enrolled in this observational study. The assessment of radial pressure pulse (RPP) was performed before and after chemotherapy. The correlation between the spectral energy (SE0-10 Hz, SE10-50 Hz, and SE13-50 Hz) of the RPP at six diagnosis positions and the blood cell counts before and after chemotherapy were analyzed.

Study Timeline

• Study Start: 2015-07-01
• Primary Completion: 2016-06-30
• Study Completion: 2016-06-30
• Status Verified: 2022-06
• Study First Submitted: 2022-06-28
• Study First Submitted QC: 2022-06-28
• Last Update Submitted: 2022-06-28
• Study First Posted: 2022-07-01
• Last Update Posted: 2022-07-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 35

Inclusion Criteria

• Patients with cancer diagnosed through pathological histology
• Patients with cancer under chemotherapy and Integrated Chinese Medicine With Western Medicine
• Patients with an Eastern Cooperative Oncology Group Performance score of 0-2
• Patients having normal liver and kidney functions and electrocardiography and eligible for chemotherapy with normal bone marrow hematopoietic function
• Patients who were voluntarily involved in this study

Exclusion Criteria

• Cases that did not meet the inclusion criteria
• Patients who could not cooperate with pulse diagnosis
• Patients with underlying diseases such as chronic obstructive pulmonary disease, cardiac failure, chronic renal failure, cirrhosis, etc.
• Patients with severe infection
• Patients with severe cachexia

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Chemotherapy-induced Hematologic Toxicity	one month	the blood cell count before and after chemotherapy was collected for measurement of severity of myelosuppression